查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1617226

肺癌藥物市場至2030年的預測：按類型、治療類型、通路和地區分類的全球分析

Lung Cancer Therapeutic Market Forecasts to 2030 - Global Analysis By Type (Non-Small Cell Lung Cancer, Small Cell Lung Cancer and Other Types), Therapy Type, Distribution Channel and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的資料，2024年全球肺癌藥物市場規模為 375億美元，預計到2030年將達到 810億美元，預測期內年複合成長率為 13.7%。

肺癌藥物包括一系列目的是控製或治癒肺癌（在肺部組織中形成的惡性腫瘤）的治療和介入。這些治療包括手術、放射線治療和化療。標靶治療使用蛋白酪氨酸激酶抑制劑和單株抗體等藥物來針對癌細胞內的特定基因突變或異常。免疫療法使用查核點抑制劑等藥物，利用人體的免疫系統來辨識並攻擊癌細胞。整合多種治療方法的聯合治療已在疾病晚期顯示出療效。個人化醫療透過根據患者的基因譜量身訂做治療計劃來支持這些治療。

美國肺臟協會2022年的一份報告發現，雖然這種疾病仍然是女性和男性癌症死亡的第一大原因，但過去5年全國的存活率從21%增加到25%，但仍顯著低於20%。

肺癌發生率增加

肺癌患者數量的不斷增加，對多種治療方法，包括手術、化療、放射線治療、標靶治療、免疫治療等。此外，對診斷工具和影像技術等早期檢測和篩檢解決方案的需求也在不斷成長。這些工具在早期檢測肺癌和確定最有效的治療策略方面發揮著重要作用。這種需求導致市場成長並增加製藥公司和醫療保健提供者的收益。

副作用和功效問題

肺癌治療通常與嚴重的副作用有關，例如噁心、疲勞、免疫抑制和器官毒性，這些副作用可能會降低患者的依從性和次優的治療結果。如果這些治療無法產生預期的結果或疾病進展有限，患者和醫療保健提供者可能不願意繼續治療，導致治療中斷率很高，並且需要可能更昂貴的替代治療，阻礙市場成長。

醫學研究進展

基因組學和分子生物學的發展導致了針對具有特定基因突變的癌細胞的標靶治療的發展，與傳統化療相比，提高了療效並減少了副作用。免疫療法，例如免疫查核點抑制劑，有可能顯著改變非小細胞肺癌的治療模式，增強人體的免疫反應並延長存活期。此外，精準醫療可以根據患者獨特的癌症類型和基因組成製定個人化治療計劃，推動市場成長。

治療費用高

肺癌治療的高昂費用是一種經濟負擔，尤其是對於沒有保險的患者來說，導致治療延遲或錯過、健康結果不佳以及存活率較低。這加劇了健康不平等，因為低收入和用戶不太可能獲得所需的治療。因此，肺癌治療的經濟負擔顯著影響患者的福祉和醫療保健系統的效率。

COVID-19 的影響

COVID-19大流行對肺癌藥物市場產生了重大影響，由於醫療保健系統的壓力和患者的猶豫，導致診斷和治療中斷。選擇性治療被推遲，降低了早期發現率和治療啟動率。臨床試驗被推遲或面臨招募問題，減緩了藥物開發。然而，大流行加速了遠端醫療和數位醫療解決方案的採用，這在一定程度上緩解了治療中斷的情況。

免疫治療領域預計將成為預測期內最大的市場

免疫查核點抑制劑，如Pembrolizumab和Nivolumab，是治療非小細胞肺癌（NSCLC）的關鍵成分，可提高存活率並成為晚期護理標準，使其成為免疫治療領域的重要組成部分。事實證明，免疫療法與化療、標靶治療和其他藥物的組合在某些患者群體中比單一療法更有效，可以改善患者的預後。

預計醫院藥學區隔在預測期內將經歷最高的年複合成長率。

預計醫院藥房區隔在預測期內將以最高的年複合成長率成長。由於醫院藥局經常參與臨床試驗，因此可以儘早獲得新的治療方法，並將最新的治療方法引進臨床實踐。此外，從這些業務中收集的資料有助於了解治療效果和患者結果，影響未來的藥物開發和市場需求。

佔有率最大的地區

在預測期內，北美，尤其是美國，預計將佔據最大的市場佔有率，因為該地區製藥公司和研究機構高度集中，並且是創新肺癌治療藥物開發和核准的主要企業。 FDA 和加拿大衛生署等關鍵監管機構的存在促進了新藥的快速核准和推出，使北美成為尖端癌症藥物的中心。

年複合成長率最高的地區：

預計亞太地區在預測期內將實現最高的年複合成長率。同時，亞太地區，特別是富裕國家，日益將標靶治療和免疫療法等先進治療納入標準治療方案。然而，肺癌治療的可用性因地區而異，日本和韓國等已開發國家比印度和印尼等低收入國家更容易獲得創新治療方法，但存活率較低，這可能會影響治療結果。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之1：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多3家公司）
    • 主要企業SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭標基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二次研究資訊來源
    • 先決條件

第3章 市場趨勢分析

  • 促進要素
  • 抑制因素
  • 機會
  • 威脅
  • 新興市場
  • COVID-19 的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入業者的威脅
  • 競爭公司之間的敵對關係

第5章 全球肺癌藥物市場：依類型

  • 非小細胞肺癌
    • 腺癌
    • 鱗狀細胞癌
    • 大細胞癌
  • 小細胞肺癌
  • 其他類型

第6章 全球肺癌藥物市場：依治療類型

  • 免疫療法
    • Durvalumab
    • Nivolumab
    • Atezolizumab
    • Pembrolizumab
  • 標靶治療
    • Bevacizumab
    • Dabrafenib/Trametinib
    • Erlotinib
    • Osimertinib
    • 其他標靶治療
  • 化療
  • 放射治療
  • 其他治療方法

第7章 全球肺癌藥物市場：依通路分類

  • 零售藥房
  • 醫院藥房
  • 網路藥房
  • 專業癌症治療中心
  • 其他通路

第8章 全球肺癌藥物市場：依地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東、非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第9章 主要進展

  • 合約、夥伴關係、合作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第10章 公司概況

  • Abbvie
  • Amgen Inc.
  • AstraZeneca
  • Boehringer Ingelheim
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Eli Lilly and Company
  • Genentech
  • Hoffmann-La Roche
  • Johnson & Johnson
  • Merck & Co.
  • Millennium Pharmaceuticals, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
Product Code: SMRC28106

According to Stratistics MRC, the Global Lung Cancer Therapeutics Market is accounted for $37.5 billion in 2024 and is expected to reach $81.0 billion by 2030 growing at a CAGR of 13.7% during the forecast period. Lung cancer therapeutics encompasses various treatments and interventions aimed at managing or curing lung cancer, a malignancy originating in lungs' tissues. These treatments include surgery, radiation therapy, and chemotherapy. Targeted therapies focus on specific genetic mutations or abnormalities in cancer cells, using drugs like tyrosine kinase inhibitors and monoclonal antibodies. Immunotherapy uses the body's immune system to recognize and attack cancer cells, often through checkpoint inhibitors. Combination therapies, integrating various treatment modalities, have shown efficacy in advanced stages of the disease. Personalized medicine supports these treatments by tailoring treatment plans based on the patient's genetic profile.

According to the 2022 report by the American Lung Association, while the disease remains the leading cause of cancer deaths among women and men, the survival rate over the past five years has increased from 21% nationally to 25% yet remains significantly lower among communities of colour at 20%.

Market Dynamics:

Driver:

Increasing incidence of lung cancer

The rise in lung cancer cases has fueled a surge in demand for various treatment options, including surgeries, chemotherapy, radiation therapy, targeted therapy, and immunotherapy. Moreover the demand for early detection and screening solutions, such as diagnostic tools and imaging technologies, is also growing, as these tools play a crucial role in identifying lung cancer early and determining the most effective treatment course. This demand has led to market growth and increased revenue for pharmaceutical companies and healthcare providers.

Restraint:

Side effects and efficacy concerns

Lung cancer treatments often have severe side effects like nausea, fatigue, immune suppression, and organ toxicity, which can reduce patient adherence and lead to suboptimal outcomes. If these treatments don't yield expected results or have limited disease progression, patients and healthcare providers may hesitate to continue, resulting in higher treatment discontinuation rates and the need for alternative, potentially more expensive, treatments hampering the market growth.

Opportunity:

Advancements in medical research

Advances in genomics and molecular biology have led to the development of targeted therapies targeting cancer cells with specific genetic mutations, improving efficacy and reducing side effects compared to traditional chemotherapy. Immunotherapy, such as immune checkpoint inhibitors, has significantly changed the treatment landscape for NSCLC, enhancing the body's immune response and potentially extending survival. In addition precision medicine has enabled personalized treatment plans based on a patient's specific cancer type and genetic makeup encourages the growth of the market.

Threat:

High treatment costs

High lung cancer treatment costs can cause financial burdens for patients, especially those without insurance, leading to delayed or missed treatment, poorer health outcomes, and reduced survival rates. This exacerbates health inequities, as low-income or underinsured populations are less likely to receive necessary care. Consequently, the economic burden of lung cancer therapy significantly impacts patient well-being and healthcare system efficiency.

Covid-19 Impact

The COVID-19 pandemic had a notable impact on the Lung Cancer Therapeutics Market, leading to disruptions in diagnosis and treatment due to healthcare system strains and patient hesitancy. Elective procedures were delayed, reducing early detection and treatment initiation rates. Clinical trials were postponed or faced recruitment challenges, slowing drug development. However, the pandemic accelerated the adoption of telemedicine and digital health solutions, which partially mitigated treatment interruptions.

The immunotherapy segment is expected to be the largest during the forecast period

The immunotherapy segment is projected to account for the largest market share during the projection period owing to particularly immune checkpoint inhibitors like pembrolizumab and nivolumab, is a key component in treating non-small cell lung cancer (NSCLC), improving survival rates and becoming the standard treatment for advanced stages. Combining immunotherapy with chemotherapy, targeted therapy, or other agents has proven more effective than monotherapy for certain patient groups, improving patient outcomes.

The hospital pharmacies segment is expected to have the highest CAGR during the forecast period

During the projection period, the hospital pharmacies segment is expected to grow at the highest CAGR because hospital pharmacies often participate in clinical trials, providing early access to new therapies and integrating the latest treatment options into clinical practice. Additionally the data collected from these operations can help understand treatment efficacy and patient outcomes, influencing future drug development and market demand.

Region with largest share:

During the estimation period, the North America region is expected to capture the largest market share owing to North America, particularly the U.S., is leading in drug development and approval of innovative lung cancer treatments, with a high concentration of pharmaceutical companies and research institutions. The presence of major regulatory bodies like the FDA and Health Canada facilitates quick approval and introduction of new drugs, making North America a hub for cutting-edge cancer therapeutics.

Region with highest CAGR:

The Asia Pacific region is projected to achieve the highest CAGR during the forecast period because Asia Pacific region is increasingly incorporating advanced therapies like targeted therapies and immunotherapy into standard treatment protocols, particularly in wealthier countries. However, there is variability in lung cancer therapeutic availability across the region, with developed countries like Japan and South Korea having more access to innovative treatments than lower-income nations like India and Indonesia, which can affect survival rates and treatment outcomes.

Key players in the market

Some of the key players in Lung Cancer Therapeutics market include Abbvie , Amgen Inc., AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, Genentech, Hoffmann-La Roche, Johnson & Johnson, Merck & Co., Millennium Pharmaceuticals, Inc., Novartis AG, Pfizer Inc., Sanofi and Teva Pharmaceutical Industries Ltd.

Key Developments:

In November 2024, Novartis announced that the European Commission (EC) has approved Kisqali(R) (ribociclib) in combination with an aromatase inhibitor (AI) for the adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (EBC) at high risk of recurrence.

In June 2024, AbbVie announced the acquisition of Celsius Therapeutics, Inc. ("Celsius"), a privately held biotechnology company pioneering new therapies for patients with inflammatory disease. Celsius' lead investigational asset is CEL383, a potential first-in-class anti-TREM1 antibody that has completed a Phase 1 clinical study for the treatment of IBD.

Types Covered:

  • Non-Small Cell Lung Cancer
  • Small Cell Lung Cancer
  • Other Types

Therapy Types Covered:

  • Immunotherapy
  • Targeted Therapy
  • Chemotherapy
  • Radiotherapy
  • Other Therapy Types

Distribution Channels Covered:

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies
  • Specialty Cancer Treatment Centers
  • Other Distribution Channels

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Lung Cancer Therapeutics Market, By Type

  • 5.1 Introduction
  • 5.2 Non-Small Cell Lung Cancer
    • 5.3.1 Adenocarcinoma
    • 5.3.2 Squamous Cell Carcinoma
    • 5.3.3 Large Cell Carcinoma
  • 5.3 Small Cell Lung Cancer
  • 5.4 Other Types

6 Global Lung Cancer Therapeutics Market, By Therapy Type

  • 6.1 Introduction
  • 6.2 Immunotherapy
    • 6.2.1 Durvalumab
    • 6.2.2 Nivolumab
    • 6.2.3 Atezolizumab
    • 6.2.4 Pembrolizumab
  • 6.3 Targeted Therapy
    • 6.3.1 Bevacizumab
    • 6.3.2 Dabrafenib/trametinib
    • 6.3.3 Erlotinib hydrochloride
    • 6.3.4 Osimertinib
    • 6.3.5 Other Targeted Therapies
  • 6.4 Chemotherapy
  • 6.5 Radiotherapy
  • 6.6 Other Therapy Types

7 Global Lung Cancer Therapeutics Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Retail Pharmacies
  • 7.3 Hospital Pharmacies
  • 7.4 Online Pharmacies
  • 7.5 Specialty Cancer Treatment Centers
  • 7.6 Other Distribution Channels

8 Global Lung Cancer Therapeutics Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Abbvie
  • 10.2 Amgen Inc.
  • 10.3 AstraZeneca
  • 10.4 Boehringer Ingelheim
  • 10.5 Bristol-Myers Squibb Company
  • 10.6 Celgene Corporation
  • 10.7 Eli Lilly and Company
  • 10.8 Genentech
  • 10.9 Hoffmann-La Roche
  • 10.10 Johnson & Johnson
  • 10.11 Merck & Co.
  • 10.12 Millennium Pharmaceuticals, Inc.
  • 10.13 Novartis AG
  • 10.14 Pfizer Inc.
  • 10.15 Sanofi
  • 10.16 Teva Pharmaceutical Industries Ltd.

List of Tables

  • Table 1 Global Lung Cancer Therapeutics Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Lung Cancer Therapeutics Market Outlook, By Type (2022-2030) ($MN)
  • Table 3 Global Lung Cancer Therapeutics Market Outlook, By Non-Small Cell Lung Cancer (2022-2030) ($MN)
  • Table 4 Global Lung Cancer Therapeutics Market Outlook, By Adenocarcinoma (2022-2030) ($MN)
  • Table 5 Global Lung Cancer Therapeutics Market Outlook, By Squamous Cell Carcinoma (2022-2030) ($MN)
  • Table 6 Global Lung Cancer Therapeutics Market Outlook, By Large Cell Carcinoma (2022-2030) ($MN)
  • Table 7 Global Lung Cancer Therapeutics Market Outlook, By Small Cell Lung Cancer (2022-2030) ($MN)
  • Table 8 Global Lung Cancer Therapeutics Market Outlook, By Other Types (2022-2030) ($MN)
  • Table 9 Global Lung Cancer Therapeutics Market Outlook, By Therapy Type (2022-2030) ($MN)
  • Table 10 Global Lung Cancer Therapeutics Market Outlook, By Immunotherapy (2022-2030) ($MN)
  • Table 11 Global Lung Cancer Therapeutics Market Outlook, By Durvalumab (2022-2030) ($MN)
  • Table 12 Global Lung Cancer Therapeutics Market Outlook, By Nivolumab (2022-2030) ($MN)
  • Table 13 Global Lung Cancer Therapeutics Market Outlook, By Atezolizumab (2022-2030) ($MN)
  • Table 14 Global Lung Cancer Therapeutics Market Outlook, By Pembrolizumab (2022-2030) ($MN)
  • Table 15 Global Lung Cancer Therapeutics Market Outlook, By Targeted Therapy (2022-2030) ($MN)
  • Table 16 Global Lung Cancer Therapeutics Market Outlook, By Bevacizumab (2022-2030) ($MN)
  • Table 17 Global Lung Cancer Therapeutics Market Outlook, By Dabrafenib/trametinib (2022-2030) ($MN)
  • Table 18 Global Lung Cancer Therapeutics Market Outlook, By Erlotinib hydrochloride (2022-2030) ($MN)
  • Table 19 Global Lung Cancer Therapeutics Market Outlook, By Osimertinib (2022-2030) ($MN)
  • Table 20 Global Lung Cancer Therapeutics Market Outlook, By Other Targeted Therapies (2022-2030) ($MN)
  • Table 21 Global Lung Cancer Therapeutics Market Outlook, By Chemotherapy (2022-2030) ($MN)
  • Table 22 Global Lung Cancer Therapeutics Market Outlook, By Radiotherapy (2022-2030) ($MN)
  • Table 23 Global Lung Cancer Therapeutics Market Outlook, By Other Therapy Types (2022-2030) ($MN)
  • Table 24 Global Lung Cancer Therapeutics Market Outlook, By Distribution Channel (2022-2030) ($MN)
  • Table 25 Global Lung Cancer Therapeutics Market Outlook, By Retail Pharmacies (2022-2030) ($MN)
  • Table 26 Global Lung Cancer Therapeutics Market Outlook, By Hospital Pharmacies (2022-2030) ($MN)
  • Table 27 Global Lung Cancer Therapeutics Market Outlook, By Online Pharmacies (2022-2030) ($MN)
  • Table 28 Global Lung Cancer Therapeutics Market Outlook, By Specialty Cancer Treatment Centers (2022-2030) ($MN)
  • Table 29 Global Lung Cancer Therapeutics Market Outlook, By Other Distribution Channels (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.